Janux Therapeutics
JANX
46 hedge funds and large institutions have $542M invested in Janux Therapeutics in 2021 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 19 increasing their positions, 9 reducing their positions, and 5 closing their positions.
111% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 9
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
2.4% more ownership
Funds ownership: 63.68% → 66.08% (+2.4%)
2% more funds holding
Funds holding: 45 → 46 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less capital invested
Capital invested by funds: $571M → $542M (-$29.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$28.8M |
| 2 |
BlackRock
New York
|
+$4.33M |
| 3 |
Cerity Partners
New York
|
+$3.16M |
| 4 |
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
|
+$943K |
| 5 |
State Street
Boston,
Massachusetts
|
+$774K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$13.2M |
| 2 |
SG Americas Securities
New York
|
-$1.42M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$1.3M |
| 4 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
-$1.28M |
| 5 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
-$884K |
JANX Hedge Fund Activity: Q4 2021 in Review
46 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Janux Therapeutics (JANX) for Q4 2021, worth a combined $542M — down 5.2% from $571M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new JANX positions and 5 closed out — a net gain of 1 holder — while 19 added to existing stakes and 9 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $28.8M. The largest seller was OrbiMed, cutting an estimated $13.2M.
- 46 institutional investors held Janux Therapeutics (JANX) as of Q4 2021, up from 45 in Q3 2021.
- Funds reported $542M of Janux Therapeutics stock for Q4 2021, down 5.2% quarter-over-quarter.
- 6 funds opened new Janux Therapeutics positions in Q4 2021 and 5 closed out, a net change of +1 holder.
- The largest Janux Therapeutics buyer in Q4 2021 was Fidelity Investments, an estimated $28.8M added.
- The largest Janux Therapeutics seller in Q4 2021 was OrbiMed, an estimated $13.2M sold.
Based on aggregated 13F filings for Q4 2021.